JP2009539988A - イオンチャネルの調節因子として有用なチエノピリミジン - Google Patents

イオンチャネルの調節因子として有用なチエノピリミジン Download PDF

Info

Publication number
JP2009539988A
JP2009539988A JP2009515453A JP2009515453A JP2009539988A JP 2009539988 A JP2009539988 A JP 2009539988A JP 2009515453 A JP2009515453 A JP 2009515453A JP 2009515453 A JP2009515453 A JP 2009515453A JP 2009539988 A JP2009539988 A JP 2009539988A
Authority
JP
Japan
Prior art keywords
ring
independently
compound
pain
cor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009515453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539988A5 (https=
Inventor
レブ ティー．ディー． ファニング，
プラモッド ジョシ，
ポール クレニッツキー，
アンドレアス ターミン，
ディーン ウィルソン，
ユーリアン チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2009539988A publication Critical patent/JP2009539988A/ja
Publication of JP2009539988A5 publication Critical patent/JP2009539988A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2009515453A 2006-06-12 2007-06-12 イオンチャネルの調節因子として有用なチエノピリミジン Pending JP2009539988A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81276506P 2006-06-12 2006-06-12
PCT/US2007/013776 WO2007146284A2 (en) 2006-06-12 2007-06-12 Thienopyrimidines useful as modulators of ion channels

Publications (2)

Publication Number Publication Date
JP2009539988A true JP2009539988A (ja) 2009-11-19
JP2009539988A5 JP2009539988A5 (https=) 2010-07-15

Family

ID=38828498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515453A Pending JP2009539988A (ja) 2006-06-12 2007-06-12 イオンチャネルの調節因子として有用なチエノピリミジン

Country Status (12)

Country Link
US (1) US8883781B2 (https=)
EP (1) EP2043654A2 (https=)
JP (1) JP2009539988A (https=)
KR (1) KR20090021218A (https=)
CN (1) CN101500575A (https=)
AU (1) AU2007258313A1 (https=)
CA (1) CA2654842A1 (https=)
IL (1) IL195861A0 (https=)
MX (1) MX2008015908A (https=)
NO (1) NO20090157L (https=)
RU (1) RU2009100159A (https=)
WO (1) WO2007146284A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537590A (ja) * 2016-11-07 2019-12-26 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP2019537592A (ja) * 2016-11-07 2019-12-26 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US8876894B2 (en) 2006-09-19 2014-11-04 Medtronic Ventor Technologies Ltd. Leaflet-sensitive valve fixation member
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US8952034B2 (en) * 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CN103002833B (zh) 2010-05-25 2016-05-11 耶拿阀门科技公司 人工心脏瓣及包括人工心脏瓣和支架的经导管输送的内假体
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
NO3175985T3 (https=) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201114212D0 (en) 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
WO2016150806A1 (en) 2015-03-20 2016-09-29 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath
CN107530168B (zh) 2015-05-01 2020-06-09 耶拿阀门科技股份有限公司 在心脏瓣膜替换中具有降低的起搏器比例的装置和方法
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN109475419B (zh) 2016-05-13 2021-11-09 耶拿阀门科技股份有限公司 用于通过引导鞘和装载系统来递送心脏瓣膜假体的心脏瓣膜假体递送系统和方法
CN110392557A (zh) 2017-01-27 2019-10-29 耶拿阀门科技股份有限公司 心脏瓣膜模拟
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CN120152682A (zh) 2022-11-09 2025-06-13 耶拿阀门科技公司 用于顺序地部署可扩张植入物的导管系统

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149635A (ja) * 1993-10-12 1995-06-13 Eli Lilly & Co ホスファチジルイノシトール ３−キナーゼに依存する状態の治療のための製剤
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2004078733A1 (en) * 2003-03-03 2004-09-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2005003099A2 (en) * 2003-07-02 2005-01-13 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
WO2005014558A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyramidine compounds as inhibitors of voltage-gated ion channels
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2006044453A1 (en) * 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1806347A4 (en) * 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149635A (ja) * 1993-10-12 1995-06-13 Eli Lilly & Co ホスファチジルイノシトール ３−キナーゼに依存する状態の治療のための製剤
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2004078733A1 (en) * 2003-03-03 2004-09-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2005003099A2 (en) * 2003-07-02 2005-01-13 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
WO2005014558A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyramidine compounds as inhibitors of voltage-gated ion channels
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2006044453A1 (en) * 2004-10-13 2006-04-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019537590A (ja) * 2016-11-07 2019-12-26 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP2019537592A (ja) * 2016-11-07 2019-12-26 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP7098167B2 (ja) 2016-11-07 2022-07-11 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子

Also Published As

Publication number Publication date
WO2007146284A2 (en) 2007-12-21
WO2007146284A3 (en) 2008-04-03
CN101500575A (zh) 2009-08-05
EP2043654A2 (en) 2009-04-08
AU2007258313A1 (en) 2007-12-21
US20070287717A1 (en) 2007-12-13
KR20090021218A (ko) 2009-02-27
RU2009100159A (ru) 2010-07-20
IL195861A0 (en) 2009-09-01
US8883781B2 (en) 2014-11-11
MX2008015908A (es) 2009-01-28
CA2654842A1 (en) 2007-12-21
NO20090157L (no) 2009-01-12

Similar Documents

Publication Publication Date Title
JP2009539988A (ja) イオンチャネルの調節因子として有用なチエノピリミジン
US7989481B2 (en) Indane derivatives as modulators of ion channels
US8492403B2 (en) Bicyclic derivatives as modulators of voltage gated ion channels
US8372843B2 (en) Quinolines useful as modulators of ION channels
JP2012126751A (ja) イオンチャンネルの調節因子としての二環系誘導体
JP2010539244A (ja) イオンチャネルのモジュレーターとしてのピリジルスルホンアミド
JP2011503191A (ja) イオンチャネルのモジュレーターとしての複素環誘導体
JP2013100374A (ja) イオンチャネルのモジュレーターとして有用なヘテロ環式類
KR20080059292A (ko) 전압 개폐 이온 채널 조절인자로서의 바이페닐 유도체
JP2008540443A (ja) イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン
US7683065B2 (en) Pyridines useful as modulators of ion channels
US7705002B2 (en) Biaryls useful as modulators of ion channels
HK1130676A (en) Thienopyrimidines useful as modulators of ion channels

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130306